10-K Decoder · All companies

Coherus Oncology, Inc.

CHRS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$42.2M$26.4M+59.8%
Operating income−$181M−$200M+9.3%
Net income$168M$28.5M+489%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026

$Q3 2026Year earlierChange
Revenue$14.3M$11.6M+23.3%
Operating income−$33.6M−$44.3M+24.2%
Net income−$39.3M−$35.5M−10.7%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Coherus Oncology's revenue in FY2025?
$42.2M in FY2025 (Fiscal year ended Dec 31, 2025), +59.8% vs $26.4M a year earlier, per its 10-K filed Mar 2026.
Was Coherus Oncology profitable in FY2025?
Yes: net income was $168M and operating income −$181M in FY2025.
What was Coherus Oncology's revenue in Q3 2026?
$14.3M (+23.3% vs a year earlier), per its Form 10-Q filed Nov 9, 2026.